INDV-2000
Opioid Use Disorder (OUD)
Pre-clinicalEarly-stage
Key Facts
About Indivior PLC
Indivior PLC is a leader in addiction medicine, dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. The company's mission centers on delivering life-changing medicines and digital therapeutics to patients with substance use disorders and co-occurring mental illnesses. Its commercial success is anchored by SUBOXONE® film, and it is strategically expanding its portfolio with novel long-acting injectables like SUBLOCADE® and PERSERIS®, and exploring next-generation treatments. Indivior operates as a public company, navigating a complex regulatory and competitive landscape while addressing one of society's most pressing public health challenges.
View full company profileOther Opioid Use Disorder (OUD) Drugs
| Drug | Company | Phase |
|---|---|---|
| RBP-6000 (buprenorphine depot) | Indivior PLC | Approved |
| DMX-1002 (Ibogaine) | atai Life Sciences | Phase 1/2a |
| KUR-101 (Deuterated Mitragynine) | atai Life Sciences | Preclinical |